HOME       Contact Us      Hire Us       Domestic Airlines        Railway Enquiry     Railway Booking     Hotels Abroad
NEIGHBOURS CALLING:      Dubai      Malaysia     Nepal     Bhutan
indiatraveltimes.com
CORONAVIRUS CASUALTIES (Nov 30):- GLOBAL:- Total Cases: 6,34,96,623; Total Deaths: 14,71,976 Recovered: 4,38,74,616 BELGIUM:- Total Cases: 5,76,599; Total Deaths: 16,547 BRAZIL:- Total Cases: 63,35,878; Total deaths: 1,73,120 CANADA:- Total Cases: 3,74,051; Total Deaths: 12,076 CHINA:- Total Cases: 86,530; Total Deaths: 4,635 FRANCE:- Total Cases: 22,22,488; Total Deaths: 52,731 GERMANY:- Total Cases: 10,68,980; Total Deaths: 16,830 INDIA:- Total Cases: 94,62,739; Total Deaths: 1,37,649 INDONESIA:- Total Cases: 5,38,883; Total Deaths: 16,945 IRAN:- Total Cases: 9,62,070; Total Deaths: 48,246 ITALY:- Total Cases: 16,01,554; Total Deaths: 55,576 JAPAN:- Total Cases: 1,46,760; Total Deaths: 2,119 MEXICO:-Total Cases: 11,07,071; Total Deaths: 1,05,655 NETHERLANDS:- Total Cases: 5,23,478; Total Deaths: 9,376 PHILIPPINES:- Total Cases: 4,31,630; Total Deaths: 8,392 RUSSIA:- Total Cases: 22,95,654; Total Deaths: 39,895 S KOREA:- Total Cases: 34,201; Total Deaths: 526 SPAIN:-Total Cases: 16,64,945; Total Deaths: 45,069 SWEDEN:- Total Cases: 2,43,129 Total Deaths: 6,681 SWITZERLAND:-Total Cases: 3,27,072; Total Deaths: 4,753 UAE:- Total Cases: 1,68,860; Total Deaths: 572 UK:- Total Cases: 16,29,657; Total Deaths: 58,448; US:- Total Cases: 1,38,74,209; Total Deaths: 2,73,956 - India Travel Times.Com   [Estd: 1998]       * * *    Travel, More Travel, Travel Means A Million Things     * * *    
Why is the world going slow on intranasal vaccine development for coronavirus
Union Health Minister Dr Harsh Vardhan has indicated that Bharat Biotech and Serum Institute of India will pursue clinical trials of intranasal vaccines for Covid-19 in India and that they are seeking regulatory approval. While Serum Institute of India in a tieup with US' Codagenix started producing CDX-005 for trial purpose last month, Bharat Biotech has entered into an agreement with Washington University School of Medicine for another vaccine. Both are expected to go into the final stage by year-end. Yet there is a stepmotherly delay in producing this simple, effortless nasal vaccination. Because, it looks, that does not involve billions in this golden age of the pharmas. The intranasal vaccine, when made available, will truly revolutionalise covid treatment.

by RM NAIR

NEW DELHI, Oct 19: Union Health Minister Harsh Vardhan has said that Bharat Biotech and Serum Institute of India will pursue clinical trials of intranasal vaccines for Covid-19 in India in collaboration with foreign vaccine developers on receipt of regulatory approval. They will conduct trials, produce and market the intranasal vaccines.

The Minister said in his Sunday Samvaad that at present in India there is no intranasal covid vaccine under clinical trial.

However, he said, the Serum Institute of India has begun manufacturing US' Codagenix's CDX005 which is an intranasal live attenuated vaccine candidate for SARS-CoV-2. (The manufacturing is for large-scale safety and efficacy studies, in addition to preparing to meet global vaccine supply requirements, the company had said.)

The pre-clinical animal studies had already been completed last month and Codagenix expects to initiate Phase I human clinical trial in the UK by the end of 2020.

Serum Institute of India also plans to undertake the clinical development of this in India.

CDX-005 is a single dose intranasal vaccine made with a live attenuated version of the virus.

“Our live-attenuated vaccine approach is in sharp contrast to many of the more common COVID-19 immunisation strategies currently undergoing human testing, such as mRNA or virus-like-particle candidates, which only target the spike protein, or the adenovirus vectored approaches that could cause off-target effects. Moreover, CDX-005 is delivered intranasally rather than via an injection, which allows for more efficient, patient-friendly administration,” Codagenix had said.

Codagenix, Inc., is a New York-based clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies.

Vardhan said, Bharat Biotech has entered into an agreement with Washington University School of Medicine as part of which Bharat Biotech will conduct trials, produce and market an intranasal vaccine for Covid-19. The Phase I trials will take place in St Louis University's vaccines and treatment evaluation unit and Bharat Biotech on receipt of regulatory approval will pursue further stages of clinical trials in India.

Of the vaccines currently in Phase 3 trials in India, all are administered by injection and in two doses.

The prognosis

Nasal vaccine is less invasive and is quickly absorbed by the nasal mucosa. There is no fear of diseases transmission through needles and anaphylactic response associated with injections. Manufacture, distribution and administration (by self) will be easy and very cheap and quick and smooth. It will be an effortless step to stop coronavirus transmission instantly. If not sabotaged! Presently, billions and billions are siphoned off for medicines that are no cure.

Nasal vaccine has several more advantages. It will ensure systemic as well as local immunity as it directly impacts the nasal mucosa which is corona's primary breeding ground. Engaging local immunity will have immediate effect of reducing the viral load. A reduced load moving through airways by inhalation will delay replication in the lungs with the result that by then the 'sleeping' immune system would have woken up to strike down the viral invasion before it is late. A delayed human immune response to coronavirus has been found to be why the virus is so lethal. Some scientists believe the virus has the ability to evade detection by the primary immune layer and that gives it time to get entrenched before the larger immune system responds. This late immune response goes into an overdrive like a panic reaction that damages organs like kidney, heart, liver, brain etc. in what is called cytokine storm. It is not the virus that is doing the organ damage as much, its habitat being only the airways and the lungs. This is otherwise called the corona's asymptomatic advantage, which the nasal spray will break.

During the current crisis the world is passing through, coronavirus calls for a logical approach to prevention and cure as there is no medicine. Let us keep in mind one thing that this virus is not a living thing to fly into our nostrils on its own! Else, let us turn to the doctor who has gathered enough experience in the last ten months as our only Saviour.

Previous Files
ARCHIVES



Neighbours
Calling

Bhutan
Nepal
Malaysia
Dubai

Dalai Lama discharged from hospital in New Delhi
Fashion & Lifestyle
Yoga & Asanas
Fairs, Festivals & Melas
Religion & Cult
Pilgrimage
Art & Culture
History, Legends & Mythology
Ayurveda
Free Ayurveda Consultation
ARCHIVES
A Window On India
Fashion & Lifestyle
Yoga & Asanas
Fairs, Festivals & Melas
Religion & Cult
Pilgrimage
Art & Culture
History, Legends & Mythology
Ayurveda
News (Archives)
Travel News
Travel News Archives
Travel News Index

Custom Search